Abstract
Doubling Time (DT) is typically calculated for growth curves that show exponential growth, such as the cumulative number of COVID-19 cases day by day. DT represents the time it takes before the number of COVID-19 cases, in a certain country or area, doubles.
Throughout the ongoing COVID-19 outbreak, DT values are continually changing. These changes are influenced by the measures that are recommended by the health authorities and implemented by governments.
After the government-imposed shutdowns of Nordic Countries that were announced around the 12th of March 2020, we followed the development of the DT in the region. Governments put in place measures never before experienced during peace time; working from home, closed schools and kindergartens, travel bans and social distancing. We conducted analyses to evaluate the effectiveness of these measures. Does it work? The initial set of results following the shutdown are encouraging, demonstrating a trend towards slower growth; however, this could be reversed if the measures that are in place now are abandoned too early. Premature optimism can be very costly. In this report we describe a method for monitoring the epidemic in real time and evaluating the effectiveness of the implemented measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no external funding was received
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
THe manuscript is based on Open data.
https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases
